Form 4: Amylyx Pharmaceuticals Director Granted 25,000 Stock Options

Amylyx Pharmaceuticals, Inc. Director Daphne Quimi was granted 25,000 stock options with an exercise price of $5.05, vesting by June 2026 or the next annual meeting.

Summary

• Daphne Quimi, a Director at Amylyx Pharmaceuticals, Inc. (AMLX), was granted 25,000 stock options.
• The options have an exercise price of $5.05 per share.
• The transaction date for this grant was June 5, 2025.
• The shares subject to this option will vest in full upon the earlier of June 5, 2026, or the date of the next annual meeting, contingent on Ms. Quimi's continuous service to the Issuer.
• The options have an expiration date of June 4, 2035.
• Following this transaction, Ms. Quimi beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it indicates standard corporate governance practice of aligning director interests with shareholders through equity compensation, without any negative implications.

Positives

• The grant of stock options aligns the interests of Director Daphne Quimi with those of shareholders, as the options gain value if the company's stock price increases.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The future outlook for the granted options is tied to the vesting schedule, which is expected to be completed by June 5, 2026, or the date of the next annual meeting, provided the director maintains continuous service.

Industry Context

This Form 4 filing represents a routine equity compensation event for a director in the biotechnology or pharmaceutical industry. Granting stock options is a common method for companies to incentivize and retain key personnel, including board members, by linking their compensation to the company's long-term performance.

Comparison to Industry Standards

• The granting of stock options to directors is a standard practice across publicly traded companies, particularly in growth-oriented sectors like pharmaceuticals, to align director incentives with shareholder value creation.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor future dilution if exercised, but it also serves to align the director's interests with shareholder value creation.
• Director (Daphne Quimi): Receives equity compensation, incentivizing long-term commitment and performance.

Next Steps

• The granted stock options will vest upon the earlier of June 5, 2026, or the date of the next annual meeting, subject to continuous service.

Key Dates

Keywords

Amylyx Pharmaceuticals, AMLX, Stock Option, Director, Equity Compensation, Insider Transaction, Form 4